Marinomed Biotech AG

As of June 30, 2024, Marinomed Biotech AG carries a market capitalization of 19.41M, placing it among publicly traded companies globally. Its enterprise value stands at 47.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Marinomed Biotech AG's next confirmed earnings release is scheduled for April 21, 2027.

As of June 30, 2024, Marinomed Biotech AG has 1.55M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 3.01, and the price-to-book ratio stands at -0.94.

These figures are as of June 30, 2024. The EV/Sales ratio of 7.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 47.59M versus a market cap of 19.41M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Marinomed Biotech AG maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -141.60, indicating conservative leverage, while an interest coverage ratio of -2.56 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -96.83, reflecting losses generated across the asset base. The company generates approximately 125,246.83 in revenue per employee across its workforce of 51.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.76 indicates how many times Marinomed Biotech AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, Marinomed Biotech AG recorded 4,000.00 in income tax expense. The company reported a pretax loss of -14.11M and -14.12M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 23, 2026, Marinomed Biotech AG's stock has declined approximately 79.88% over the past 52 weeks. The 50-day moving average sits at 5.30, while the 200-day moving average is 12.80.

Over the twelve months ended June 30, 2024, Marinomed Biotech AG generated 6.42M in revenue and converted that into -14.12M in net income, yielding earnings per share of -9.18. EBITDA reached -4.79M, while operating income came in at -5.46M.

As of June 30, 2024, Marinomed Biotech AG holds 911,500.00 in cash and equivalents against 29.09M in total debt, resulting in a net debt position of 28.18M. Total book value stands at -20.54M, with working capital of -22.58M providing operational flexibility.

Marinomed Biotech AG produced -4.05M in operating cash flow over the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Marinomed Biotech AG posted a gross margin of 16.34, reflecting its pricing power and cost economics. The operating margin of -85.03 and net profit margin of -219.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -20.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Marinomed Biotech AG shareholders.

Marinomed Biotech AG's most recent stock split took place on March 24, 2026.

As of June 30, 2024, Marinomed Biotech AG has an Altman Z-Score of -13.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.